JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
JP Morgan analyst Brian Cheng initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $17.
JP Morgan analyst Brian Cheng initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $17.